Jacky Luiten

112 | Chapter 7 43. Pinder SE, Ellis IO: The diagnosis and management of pre ‐ invasive breast disease: ductal carcinoma in situ (DCIS) and atypical ductal hyperplasia (ADH) ‐‐ current definitions and classification. Breast Cancer Res 2003;5(5):254 ‐ 257. 44. van Dooijeweert C, van Diest PJ, Willems SM et al: Significant inter ‐ and intra ‐ laboratory variation in grading of ductal carcinoma in situ of the breast: a nationwide study of 4901 patients in the Netherlands. Breast Cancer Res Treat 2019;174(2):479 ‐ 488. 45. Doebar SC, Sieuwerts AM, de Weerd V et al: Gene Expression Differences between Ductal Carcinoma in Situ with and without Progression to Invasive Breast Cancer. Am J Pathol 2017; 187(7):1648 ‐ 1655. 46. Nofech ‐ Mozes S, Hanna W, Rakovitch E: Molecular Evaluation of Breast Ductal Carcinoma in Situ with Oncotype DX DCIS. Am J Pathol 2018;189(5):975 ‐ 980. 47. Rakovitch E, Gray R, Baehner FL et al: Refined estimates of local recurrence risks by DCIS score adjusting for clinicopathological features: a combined analysis of ECOG ‐ ACRIN E5194 and Ontario DCIS cohort studies. Breast Cancer Res Treat 2018;169(2):359 ‐ 369. 48. Van Zee KJ, Zabor EC, Di Donato R et al: Comparison of Local Recurrence Risk Estimates After Breast ‐ Conserving Surgery for DCIS: DCIS Nomogram Versus Refined Oncotype DX Breast DCIS Score. Ann Surg Oncol 2019;26(10):3282 ‐ 3288. 49. Elshof LE, Schmidt MK, Rutgers EJT et al: Cause ‐ specific Mortality in a Population ‐ based Cohort of 9799 Women Treated for Ductal Carcinoma In Situ. Ann Surg 2018;267(5):952 ‐ 958.